(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Solid Tumor. According to GlobalData, Phase III drugs for Solid Tumor have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Cedazuridine + decitabine)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Cedazuridine + decitabine) overview

Cedazuridine and Decitabine (Inqovi) is a fixed dose combination act as an anti-neoplastic agent. it is formulates ad film coated tablets for oral route of administration. Inqovi is indicated for the treatment of adult patients with myelodysplastic syndrome with french american british subtypes refractory anemia with ringed sideroblast, refractory anemia with excess blasts and chronic myelomonocytic leukemia.

ASTX-727 (fixed dose combination of decitabine and cedazuridine (E-7727)) is under development for the treatment of metastatic mucosal melanoma, metastatic castrate resistant prostate cancer (mCRPC), newly diagnosed acute myeloid leukemia (AML), newly diagnosed chronic myeloid leukemia, relapsed and refractory acute myeloid leukemia, peripheral nerve sheath tumor (neurofibrosarcoma), low grade gliomas, triple negative breast cancer and hormone resistant/HER2-negative metastatic breast cancer, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), myeloproliferative neoplasms, relapsed and refractory overlap syndromes and solid tumors. The drug candidate formulated as tablet and is administered orally in the form of tablet. Decitabine is a cytidine antimetabolite analogue that inhibits DNA methyltransferase-1. E-7727 is a new molecular entity (NME) that inhibits cytidine deaminase (CDA) activity. It is developed based on Pyramid technology.

Otsuka Pharmaceutical overview

Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. It’s nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.

For a complete picture of (Cedazuridine + decitabine)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.